Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Biologic obtains $1.6m sales order from India
China Biologic has received sales orders on all the products that have been registered under the Central Drugs Standard Control Organization, the drug control administration in India. Those
China Biologic has received sales orders on all the products that have been registered under the Central Drugs Standard Control Organization, the drug control administration in India. Those
DuraSite is a synthetic polymer of cross-linked polyacrylic acid that stabilizes small molecules in an aqueous matrix, allowing for targeted and sustained administration. By increasing the time that
Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera. Under a second agreement, Celera will receive royalties on the sale of
Approximately 230 patients were enrolled to this study, randomized into three groups treated with 0.1mg and 4mg of CF101, and placebo. Patients are taking the drug for 12
According to the company, the new high-capacity immunoassay system provides laboratories with a new system to address their quality, labor and cost challenges. The Vitros 3600 is expected
William Garner, CEO of Urigen Pharmaceuticals, said: “In co-operation with the University of California at San Diego (UCSD), we have amended the annual license payments to ensure that
Each share of Pediatrix will become a share of Mednax, and will trade on the New York Stock Exchange under the ticker symbol ‘MD’, when the US securities
The drug candidate is an antimicrobial peptide named Plectasin NZ2114 that targets the treatment of infections such as pneumonia and septicemia, caused by bacteria like Staphylococcus and Streptococcus.
In connection with the acquisition, Ligand issued approximately 18m shares of Ligand common stock to Pharmacopeia stockholders, or 0.60 shares for each outstanding Pharmacopeia share, as well as
Serbian oncology centers participating in the trial include the Clinical Hospital Center Benzanijska Kosa in Belgrade, the Clinic for Pulmonary Diseases and TB ‘Knez Selo’ in Nis, and